N/A N=18 The Happy Older Latinos Are Active (HOLA) Health Promotion Study in HIV-Infected Latino Men
Human Immunodeficiency Virus · Cardiometabolic Risk
Primary: Number of Eligible Participants Refusing to Participate. — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=139 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Cutaneous T-Cell Lymphoma
Primary: Overall Response Rate of Participants Using the Modified Severity-Weighted Assessment Tool (mSWAT) — 16.7; 20.3; 18.5 percentage
Phase 4 N=30 A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)
Parkinsons Disease
Primary: Change in the Mean Daily Overactive Bladder-Symptom Composite Score. — -3.2; -8.9 units on a scale
Phase 3 N=454 Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
Primary: Participants Who Survived Without Requiring Invasive Mechanical Ventilation From Day 3 to Day 29, Primary Analysis — 198; 191 Participants — p=0.2874
N/A N=91 Mitral Implantation of TRAnscatheter vaLves
Mitral Valve Disease
Primary: Technical Success at Exit From the Cath Lab. — 23; 20; 30 Participants
N/A N=30 A Positive Psychology Intervention for Patients With Multiple Sclerosis
Multiple Sclerosis
Primary: Percentage of PP Exercises Completed by Subjects — 93; 93 percentage of exercises completed
N/A N=30 Written vs Electronic Safety Planning Study
Suicidal Ideation · Suicide Attempt · Mental Health
Primary: Acceptability of Intervention — 14; 16 Participants
N/A N=181 Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System
Diabetes Mellitus, Type 1
Primary: Treatment Satisfaction: Accu-Chek® Micropump System vs. MDI, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score — 105.9; 94.8…
Phase 2 N=82 Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
Schizophrenia
Primary: Prepulse Inhibition (PPI) — 22.629; 41.162; 50.626; 50.626 % inhibition of startle
N/A N=229 Study Comparing Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy (CRT) for Spinal Metastases
Spinal Metastases
Primary: Phase III: Complete Pain Response at 3 Months Post-radiation — 16; 40; 29; 20 Participants — p=0.0002
Phase 2 N=173 Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
Myelodysplastic Syndrome · Iron Overload
Primary: Number of Participants Reporting Adverse Events — 171 Participants
Phase 2 N=67 A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
Asthma
Primary: FEV1 Area Under the Curve Between 0 and 12 h [AUC(0-12h)], Normalized by Time -- Change From Baseline to Post Dose Day 14 — 0.174; 0.221; 0.197; 0.231 Litres — p=<0.001
Phase 2 N=77 Treatment of Psychosis and Agitation in Alzheimer's Disease
Alzheimer's Disease · Psychosis · Agitation
Primary: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score — 3.2; 2.5 score on a scale — p=0.53
Phase 3 N=114 Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment
Covid19
Primary: Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS. — 7; 7; 2; 2 days — p=0.05
Phase 2 N=9 Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
Advanced Solid Tumors · Acute Myeloid Leukemia
Primary: Number of Participants With Adverse Events — 2; 3; 3; 1 Participants